Edwards Lifesciences Corporation EW recently gained CE Mark for its PASCAL Precision transcatheter valve repair system used to treat mitral and tricuspid regurgitation. The PASCAL Precision system is ...

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

Interventional cardiologists have performed a world-first procedure. They implanted a new device called the Pascal system in a patient with tricuspid regurgitation -- a condition in which the valve ...

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...

BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

TORONTO, July 12, 2024 /CNW/ - Edwards Lifesciences (Canada) Inc today announced Health Canada's approval of the company's PASCAL Precision transcatheter valve repair system for the percutaneous ...

Interventional cardiologist Dr. Neil Fam of St. Michael's Hospital published the report of implanting Pascal system in a patient with tricuspid regurgitation. Dr. Fam implanted a new device called the ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...